Developing Site-specifically Modified ADCs Using A Chemoenzymatic Approach | 83145
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

2nd International Conference on Biotechnology and Healthcare

Auckland, New Zealand

6th International Conference on Vaccines and Immunology

Geneva, Switzerland

3rd European Congress on Virology

Geneva, Switzerland
Google scholar citation report
Citations : 1600

Journal of Biotechnology & Biomaterials received 1600 citations as per google scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Developing site-specifically modified ADCs using a chemoenzymatic approach

Joint Event on 20th Global Congress on Biotechnology & 3rd International Conference on Enzymology and Molecular Biology

David Rabuka

Catalent Biologics, USA

Keynote: J Biotechnol Biomater

DOI: 10.4172/2155-952X-C2-090

We have developed the SMARTagTM technology platform, which enables precise, programmable, site-selective chemical protein modification. Leveraging the target sequence of formylglycine generating enzyme (FGE), we chemoenzymatically modify proteins to generate a precisely placed aldehyde functionality that can be chemically elaborated. Subsequently, novel ligation chemistry is employed that exploits this “aldehyde tag” site. We will present recent data on our novel protein modification platform and its application to generating novel bioconjugates, including ADCs, utilizing our new conjugation chemistries and linkers. The application of these chemistries to generate site-specifically modified bioconjugates with improved efficacy and safety profiles will be presented. Additionally, we will highlight the progress in developing conjugates with a focus on preclinical studies as well as highlight our progress in cell line development and manufacturing by using this chemoenzymatic approach

David Rabuka received a PhD in Chemistry at the University of California, Berkeley as a Chevron Fellow in the Lab of Carolyn Bertozzi. His research included developing and applying the SMARTagTM platform technology to cell surface modification. Prior to joining Bertozzi’s lab, he worked at the Burnham Institute synthesizing complex glycans followed by Optimer Pharmaceuticals, where he focused on the development of glycan and macrolide based antibiotics. He was CSO, President and Co-founder of Redwood Bioscience, where he developed novel protein conjugation methods and biotherapeutic applications such as antibody-drug conjugates. Redwood Bioscience was acquired by Catalent Pharma Solutions in Oct 2014, where he has continued to apply the SMARTagTM technology with various collaborators and partners as a Global Head of R&D. He graduated with a Double Honors BS in Chemistry and Biochemistry from the University of Saskatchewan, where he received the Dean’s Science Award, and holds an MS in Chemistry From the University of Alberta. He has authored over 45 major publications, as well as numerous book chapters and holds over 30 patents.
Email:[email protected]